Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13711178 | 0.93 | GAA (0.45) | L3MBTL1THRBATMGAAALDH1A1 | |
| SCHEMBL20767209 | 0.86 | GAA (0.38) | L3MBTL1THRBATMGAAALDH1A1 | |
| SCHEMBL27008084 | 0.86 | GAA (0.38) | L3MBTL1THRBATMGAAALDH1A1 | |
| SCHEMBL6120347 | 0.86 | GAA (0.38) | L3MBTL1THRBATMGAAALDH1A1 | |
| SCHEMBL20767257 | 0.86 | GAA (0.38) | L3MBTL1THRBATMGAAALDH1A1 | |
| SCHEMBL27008132 | 0.86 | GAA (0.38) | L3MBTL1THRBATMGAAALDH1A1 | |
| SCHEMBL29099046 | 0.86 | HPGD (0.42) | GAAALDH1A1MAPT | |
| SCHEMBL5151599 | 0.86 | HPGD (0.42) | GAAALDH1A1MAPT | |
| SCHEMBL15227428 | 0.86 | HPGD (0.42) | GAAALDH1A1MAPT | |
| SCHEMBL29099043 | 0.86 | HPGD (0.42) | GAAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149568-A1 | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | MERCK SHARP & DOHME LLC | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149568-A1 | N-substituted nonaryl-heterocyclic nmda/nr2b antagonists | GRIN2B, GRIN1, GRIN2A | L3MBTL1 4317/4885THRB 1720/4885ATM 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.